Purpose: To evaluate treatment satisfaction and compliance with pharmacologic therapy in urinary incontinence patients. Materials and Methods: An online survey was returned by 1447 individuals from a nationwide panel of adults who had previously reported treatment for incontinence symptoms and agreed to participate in survey research. Data on demographics, incontinence severity, treatment compliance, and satisfaction were obtained. Logistic regression was used to estimate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for characteristics associated with pharmacologic treatment dissatisfaction and discontinuation. Results: The sample was predominantly female (87%) and white (93%) with a mean age of 56 years. On average, patients urinated 10 times/day and experienced 16 wetting accidents in the week preceding survey. Overall, 25% reported being somewhat or very dissatisfied with treatment. Those who reported a severe effect of incontinence on their lives were most likely to be dissatisfied (OR = 2.82, 95% CI = 1.89-4.23). Discontinuation of drug treatment was reported by 45% of study subjects, with major reasons being poor efficacy (in 41.3% of discontinuations), side effects (22.4%), and cost (18.7%). Predictors for discontinuation included young age (OR = 1.8, 95% CI = 1.2-2.8), experiencing symptoms for 10 or more years (OR = 1.5, 95% CI = 1.1-2.0), and experiencing more than 16 wetting accidents in the last week (OR = 1.6, 95% CI = 1.3-2.1).
Introduction
Urinary incontinence is a disabling condition that afflicts approximately 13 million individuals in the United States [1] ; worldwide prevalence estimates vary from 10 to 50% [2] depending on the age, sex, and disease definition criteria applied [3, 4] . The associated economic costs of incontinence are substantial, with recent total estimates reaching US$12 billion [5] . More than 97% are direct costs [6] made up of diagnostic tests, doctor visits, surgery, protective measures (e.g., pads), institutionalization, and nonpharmacological and pharmacological therapy. Nonpharmacological treatments include pelvic muscle rehabilitation, bladder training/timed voiding, electrical stimulation, and surgical interventions [3, 7, 8] . First-line pharmacotherapy for urge incontinence consists of anticholinergics, including tolterodine (Detrol, Detrol LA) and oxybutynin (Ditropan, Ditropan XL) [3, 7, 8] . Stress incontinence may be pharmacologically treated with estrogen therapy and/or alpha-adrenergic agonists [9] .
For both types of incontinence, drug therapies appear to be especially effective when combined with behavioral intervention [10] .
Despite available therapies, relatively few individuals suffering from incontinence seek health care [11] [12] [13] and, of those who do, few are compliant or persist with therapy [14] [15] [16] . For example, persistence rates with oxybutynin or tolterodine were 32-44% at 1 month, 22% at 6 months, and dropped to 5-11% at 12 months in two Medicaid populations [14, 16] . Compliance rates, as reported for one of these populations, were even more alarming-less than 5% of patients were compliant at 6 months and 0.7% were adherent at 12 months [16] . As both compliance and persistence are crucial to treatment success, it is important to discover why these rates are so low. Analysis of demographic characteristics determined that patients were more likely to persist with therapy if they were young (<18 years old) or middle-aged (40-64 years), white, or their incontinence was recently diagnosed. Patients with a history of depression or urinary tract infection, or who were taking multiple drugs (for any condition) were less likely to persist with treatment. The roles of pharmacotherapy and any associated adverse events are uncertain. In one study oxybutynin favorably affected persistence over tolterodine [16] , whereas in two others oxybutynin was associated with a significantly higher risk of treatment discontinuation than was tolterodine [14, 17] .
Although prescription database analyses provide useful quantitative information about persistence with therapy, they do not provide any qualitative insight into the reasons why patients discontinue their incontinence medication [14] [15] [16] [17] [18] [19] . Given the costs related to burden of illness and the impact of urinary incontinence on quality of life and mental well being, patient dissatisfaction and discontinuation of treatment have substantial personal and economic ramifications [20, 21] , and further examination of these variables is warranted. The aim of this study was to investigate types of treatments (pharmaceutical or surgical) used by patients with urinary incontinence, their satisfaction with treatment, and the rate of and reasons for discontinuation of pharmacological treatment. We hoped that our qualitative assessment of reasons for incontinence treatment discontinuation would generate hypotheses for further research.
Methods
In collaboration with National Family Opinion (NFO) World Group, we screened an online nationwide database of 100,000 adults (at least 18 years of age) who have agreed to participate in survey research. From this group, which is representative of the US population and potentially includes any type of medical insurance coverage, we invited individuals to participate in the survey if they met the following criteria: 1) aged 18 or more years; 2) previously reported receiving prescription or over-the-counter (OTC) medications for treatment of incontinence symptoms (number of prescription fills not specified); and 3) not participating in another survey. Informed consent was implicit in the voluntary nature of the survey process.
The initial part of the survey consisted of four questions, including sex, age, duration of incontinence symptoms and timing of treatment. The remainder of the survey, which was developed specifically for this analysis, consisted of 29 questions related to incontinence (type, duration and frequency of symptoms, and overall impact of incontinence on life) and to incontinence treatment (use and type of treatment within last 4 weeks, efficacy in alleviating symptoms and improving ability to perform activities of daily living, impact of treatment of quality of life parameters [mood, relationships], discontinuation of treatment, which treatments were discontinued, occurrence and severity of any side-effects, and satisfaction). To assess impact of incontinence symptoms, patients were asked "what is the overall impact of incontinence on your life?", and given the options of "no effect," "mild effect," "moderate effect" or "severe effect." Satisfaction with treatment was evaluated on a 5-point Likert scale from "very satisfied" to "very dissatisfied." Development and evaluation of the Patient Satisfaction with Treatment scale used in this study has been described previously [22, 23] . The reliability and validity of the questionnaire was demonstrated in a group of incontinence patients (n = 891) similar to ours on the basis of age, sex, educational background, duration of symptoms, and mean urination and incontinence frequency [23] . Information on demographic variables, including ethnicity, education attainment, household income and geographic region of residence, were obtained from an initial recruitment survey sent to potential panel members.
We performed descriptive analyses, calculating the means and frequency distributions of the survey variables. To examine predictors of overall satisfaction with treatment, we compared two categories: very dissatisfied/somewhat dissatisfied versus very satisfied/ somewhat satisfied. Frequency of urination and wetting accidents were dichotomized according to the median of each distribution (Յ10 vs. >10 urinations per day and Յ16 vs. >16 wetting accidents per week). For each of these outcomes, logistic regression was used to estimate both unadjusted (i.e., crude) and adjusted odds ratios (ORs) for age, duration of incontinence symptoms, and severity of incontinence (measured as impact on life, urination frequency and wetting accident frequency). For each predictor variable, we adjusted for the other variables to examine the impact of potential confounders on the association with the outcome. Ninety-five percent confidence intervals (CIs) were calculated to describe the precision of the effect estimates obtained from the regression models. Statistical significance was indicated by the 95%CI not including 1.0.
Results
Overall, 3193 individuals were eligible for survey participation and 1447 individuals returned a completed survey, and made up the study sample in this analysis. The demographic characteristics of the study sample are summarized in Table 1 . The mean age of the study sample was 56 years; approximately a third was between the ages of 50 and 59 years. The vast majority of study participants were female (87%) and white (93%). More than half had less than a college education, a household income of less than $60,000 and resided in the mid-western or southern United States. Table 2 describes the overall distribution of duration and severity of incontinence symptoms. Very few subjects were afflicted for less than a year (1.6%) or reported no effect of incontinence on life (2.5%). On average, subjects reported urinating approximately 10 times a day and experiencing nearly 16 wetting accidents during the week prior to survey. Eighty-one percent experienced wetting accidents while laughing, sneezing, coughing, or exercising indicating some degree of stress incontinence.
Sixty-three percent of individuals had received pharmacological or surgical treatment for urinary incontinence within the last month; 30% received pharmacological or surgical treatment more than 6 months ago ( Table 3 ). The most common prescription treatment was Detrol LA (27%). Less commonly used pharmacotherapies included Ditropan XL (18%), and Ditropan (14%). Use of drugs administered or injected directly into the bladder was extremely rare (1% for each treatment type). When asked to rate overall satisfaction with incontinence treatment, 25% reported being somewhat dissatisfied or very dissatisfied (Table 4) . Forty-five percent of patients (n = 651) reported a reason for discontinuing drug treatment, the most frequent being a lack of treatment efficacy (41%). Less commonly reported reasons included sideeffects (22%), cost (19%) and other unspecified reasons (28%). Table 5 presents the crude and adjusted ORs (and 95% CIs), respectively, for the associations between age and disease severity measures and the outcome of treatment dissatisfaction. Age was not significantly associated with treatment dissatisfaction; nevertheless, there was a nonsignificant trend for subjects aged 18-39 years to be less satisfied with treatment compared with those aged 70 or more years (crude OR = 0.61; 95% CI 0.37-1.03). This association diminished with increasing age. The trend became slightly diminished on adjustment for duration of symptoms, effect of incontinence on life, urination frequency and wetting accident frequency. After adjustment, duration of symptoms appeared to have no impact on treatment dissatisfaction (OR ranged from 1.05 to 1.15), and patients with symptoms for 3 or more years had similar levels of dissatisfaction as those with symptoms less than 3 years. Compared with subjects who reported no effect or a mild effect of incontinence on their lives, subjects who reported a moderate effect were more likely to report dissatisfaction with treatment (OR = 2.61; 95%CI 1.90-3.58), whereas those who reported a severe effect were even more likely to be dissatisfied with treatment (OR = 4.21; 95% CI 2.89-6.14). Although these associations became attenuated after controlling for the other variables, the significant association persisted. The results for other measures of disease severity (i.e., urination frequency and wetting accident frequency) were consistent with these results. After adjustment, subjects who urinated more than 10 times a day and subjects who reported more than 16 wetting accidents in the past week were significantly more likely to be dissatisfied with treatment (OR = 1.81, 95%CI 1.36-2.40 and OR = 2.24, 95% CI 1.67-3.00, respectively).
Finally, we explored predictors of treatment discontinuation. Table 6 presents the crude and adjusted ORs (95% CI) for the associations between age and disease severity measures and discontinuation. As in the previous logistic regression models of dissatisfaction, frequency of urination and wetting accidents were dichotomized according to the median of each distribution (Յ10 vs. >10 urinations and Յ16 vs. >16 wetting accidents). Compared with subjects 70 years and older, subjects 18-39 years and subjects 40-49 years were significantly more likely to discontinue treatment (crude OR = 1.76; 95% CI 1.15-2.68 and crude OR = 2.12, 95% CI 1.49-3.01, respectively). In contrast, no significant association between age and treatment discontinuation was observed for subjects 50-59 years or 60-69 years. Adjustment for duration of symptoms, effect of incontinence on life, urination frequency and wetting accident frequency did not materially affect the magnitude of these associations. Duration of symptoms was weakly associated with treatment discontinuation. Compared with subjects who had experienced symptoms for less than 3 years, the OR for discontinuation in subjects with symptoms for 3 years to less than 6 years was not significant (crude OR 1.22; 95% CI 0.91-1.63). Nevertheless, the OR was significant in those with duration of symptoms 6 or more years (OR of 1.45 and 1.53; 95% CI did not include 1.0). After adjustment, those who reported a moderate or severe effect of incontinence were less likely to discontinue treatment (OR = 0.73; 95% CI 0.57-0.93). Although daily urination frequency was not associated with treatment discontinuation (adjusted OR = 1.17; 95% CI 0.92-1.48), subjects who experienced more than 16 wetting accidents in the last week were more likely to discontinue treatment than subjects who experienced up to 16 wetting accidents (adjusted OR = 1.64; 95% CI 1.27-2.11).
Discussion
We conducted an online survey of adults suffering from incontinence to assess the impact of patient and disease characteristics on satisfaction and persistence with treatment. Our findings suggest that patient dissatisfaction with treatment is strongly associated with disease severity, which we assessed in several different ways (impact of incontinence on life, urination frequency and wetting accident frequency). Because this was a crosssectional study, it is difficult to establish the temporal relationship between disease severity and satisfaction with treatment; i.e., whether severe disease leads to lack of efficacy (and thus dissatisfaction) or whether lack of efficacy leads to experience of symptoms. Because our definition of severity could have reflected treatment failure, our study sample may not accurately represent the spectrum of disease in the general population of incontinence patients. Despite this limitation, these results indicate potential inadequacies in the efficacy of frequently used pharmacotherapies. Indeed, the most commonly cited reason for discontinuing treatment was lack of efficacy. Although less common, side-effects and costs associated with treatment were also responsible for discontinuation. The overall rate of persistence in our study was 55%. Of the 796 subjects who reported not discontinuing treatment, 682 (85.7%) reported that they were currently receiving treatment or had received treatment in the last four weeks. Our persistence rate is markedly higher than in other studies which have reported persistence rates of around 10-20% over a 6-to 12-month period [14, 16] . These studies did not question patients about why they discontinued their medication and thus are difficult to compare with our study, but it is interesting that both found that the type of treatment used had a significant impact (adverse or otherwise) on persistence levels [14, 16] . We found that patients who reported a severe effect of incontinence on their lives were more likely to be dissatisfied with treatment but less likely to discontinue treatment than patients who reported no effect or a mild effect of incontinence. On the other hand, a high number of wetting accidents per week was significantly associated with both treatment dissatisfaction and treatment discontinuation. Urination frequency was significantly associated with treatment dissatisfaction but not with discontinuation. One explanation is that, although treatments are not ideally efficacious, some symptom relief is better than none, implying a substantial burden of incontinence symptoms on the lives of patients. This is consistent with past research demonstrating that urinary incontinence symptoms can severely diminish quality of life [20, 21, 24] .
Withdrawal rates for incontinence treatments in the clinical trial setting are around 10-15% over 12 weeks [25] [26] [27] , rising to 30-40% when the studies continue for 9-12 months [28, 29] . An analysis of prescription of overactive bladder or incontinence pharmacotherapies showed that the discontinuation rate was much higher during routine clinical practice-67% at 90 days, and 78% at 6 months [16] . These latter figures are more compatible with the current survey withdrawal rate of 45% than are the clinical trial data. In addition, although the clinical trial data cite adverse events as the most common reason for treatment discontinuation, we found that patients mostly ceased therapy because of a lack of drug effects. This probably reflects the artificial nature of the clinical trial setting where high levels of patient education, contact and follow-up can influence patient compliance and persistence. Patients may be more inclined to persist with a relatively ineffective therapy in a clinical trial setting than in clinical practice. Researchers have shown that implementing health education intervention programs for overactive bladder within the community can favorably influence patient compliance, but not significantly [30] . These findings highlight the difficulty of influencing patient compliance or adherence in the face of poor drug efficacy or tolerability.
Another potential reason for the lower discontinuation rates in clinical trials is careful patient selection. Our survey population included a high proportion of patients with symptoms of stress urinary incontinence, a condition which is relatively resistant to pharmacotherapy. Therefore, the high discontinuation rate for lack of efficacy seen in our study may have been a consequence of poor treatment choice by the patient's physician. In contrast, in a clinical trial, patients are carefully selected as suitable candidates for pharmacotherapy. This survey was undertaken using a volunteer, selfselected sample of subjects with incontinence. As such, we are unable to accurately determine the extent to which they, and the features of their disease, are representative of the spectrum of incontinence and its sufferers. In addition, we did not compare the features of patients who returned the completed questionnaire with those who met the inclusion criteria but did not complete the survey. Nevertheless, it is still worth noting some of the similarities between the demographic characteristics of our patient sample and those of other epidemiological surveys of incontinence populations. No single study has ever determined the prevalence of urinary incontinence (as a general term) across the whole US population. The most comprehensive epidemiological survey to date is the National Overactive BLadder Evaluation (NOBLE) Program which investigated the prevalence of overactive bladder with and without urge incontinence in more than 5000 adults representative of the US population [21] . According to this survey, the prevalence of urgencyrelated bladder control problems is similar in men and women, but women suffer from incontinence more often than men. This may explain why the vast majority of our subjects were female and why other studies of incontinence prevalence have also found that women are over-represented in comparison to men [11, 31] . Compared with NOBLE, our study contained lower percentages of Black or Hispanic subjects, although education levels were similarly represented. Age and household income comparability could not be determined because of the different ranges used.
It is important to keep in mind that survey research is particularly susceptible to response bias wherein those with a particular interest or motivation to respond may be over-represented in the final sample. If this is more likely among those who are not currently satisfied with their therapy or suffer a disproportionate impact of the illness on their life, then our results may overstate these features in the population. The online nature of the survey may also bias the results, because it can only be taken by individuals who have access and are capable of using the internet. Thus, the number of elderly subjects and/or those of low household income in our study may not sufficiently represent incontinence sufferers in these general subpopulations. Men are also underrepresented relative to the NOBLE population [21] . Care must be exercised in generalizing the results of this study beyond populations with similar characteristics.
Similarly, our survey was limited to patients who were currently taking pharmacological treatment or had received any treatment within the previous 4 weeks. Therefore, although we asked about discontinuation of any drug treatment at any time in the past, the survey was biased towards patients currently or recently receiving treatment. This may underestimate the long-term discontinuation rates with drug therapy by being biased towards: 1) patients who are newly treated and not yet discontinued; and 2) patients who are more motivated towards trying treatment again, despite a previous discontinuation. In addition, although our survey questions asked specifically about symptoms of stress incontinence (the frequency of "wetting accidents" associated with sneezing or exercise), we did not ask specifically about urinary urge incontinence (i.e., involuntary urine leakage accompanied or immediately preceded by urgency). This potentially biases our results towards a population with predominantly stress incontinence compared with other forms of incontinence or overactive bladder. Finally, our question about pharmacologic therapies was specific to prescription medication, and we did not question our survey respondents on their use of OTC medications. This was based on the fact that we were not aware of any OTC medications for incontinence at the time of the survey. Nevertheless, we cannot rule out the possibility that a proportion of 10.2% of patients who reported using "other oral agents" were taking an OTC agent.
To the best of our knowledge, this is only the second online survey used to assess incontinence in the United States. The first online interviews were conducted in 2004 and sought to understand how people managed incontinence [12] . Using very open criteria, the survey found that 32% of Americans between the age of 30 and 70 years had experienced loss of bladder control at least once in their lives, but only 13% of those with symptoms had ever been formally diagnosed and most (64%) were not using any form of treatment or product to manage their incontinence. As with our survey, women were far more likely than men to have symptoms.
In summary, lack of efficacy was the most common self-reported reason for discontinuing pharmacological treatment in this online self-selected sample of incontinence patients, predominantly women, and on multivariate analysis, the frequency of wetting accidents was associated with lack of persistence. Thus, our results indicate a substantial degree of unmet need from current therapy among those with incontinence. Other surveys have shown that women with urinary incontinence expect at least a 70% reduction in incontinence episodes to consider a treatment effective [32] , and that there can be quite a discrepancy between patients' and doctors' perception of the "bother" caused by incontinence symptoms [33] . All these findings have considerable clinical implications with regard to adequately meeting patients' needs, and help to explain the poor persistence rates with incontinence therapy seen in prescription database analyses [14, 16] . To more fully understand the reasons for lack of persistence with pharmacotherapy, future studies should focus on the links between efficacy, side-effects, quality of life, and treatment discontinuation in nontrial settings.
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